Osteoarthritis nodes (Photo credit: MyArthritis)
New research involving Irish scientists could lead to effective new treatments for the most common type of arthritis within the next five years.
Scientists based at NUI Galway are part of an EU-funded project – ADIPOA – that is investigating how stem cells from adult fat tissue may be used to activate the regeneration of cartilage. This could lead to new treatments for the condition, osteoarthritis (OA).
OA usually develops gradually over several years, and affects a number of different joints. It is characterised by a degeneration of cartilage in these joints and can be very painful.
Around 400,000 people in Ireland and 70 million in the EU are affected by the condition
According to the scientists, the phase one clinical trial has just finished and early results have so far been positive. Based on these findings, a new and effective treatment for OA could become a reality within the next few years.
“Until now there were just two possible outcomes for suffers of this progressive and debilitating disease – joint replacement surgery, in the case of advanced disease or, life-long pain management. From the clinical trials conducted so far, we have seen the first signs of finding a cure for this truly incapacitating disease which affects so many,” commented Prof Frank Barry, scientific director of the Regenerative Medicine Institute (REMEDI) at NUI Galway and a partner in the ADIPOA project.
He pointed out that using the patient’s own stem cells, the scientists were able to ‘treat their diseased joints and relieve their suffering and burden of pain’.
“While we are still in the early stages of clinical trials, the results so far are extremely positive, such that the use of stem cell therapy for osteoarthritis could become a reality for patients within the next five years,” he insisted.
The Latest on: Arthritis
via Google News
The Latest on: Arthritis
- NICE recommends Jyseleca(R) (filgotinib) on NHS in landmark decision for rheumatoid arthritison January 21, 2021 at 5:12 pm
NICE guidance, for the first time in the UK, supports access to an advanced therapy for people with moderate as well as severe rheumatoid arthritis (RA) - aiming to avoid irreversible damage as early ...
- New trial finds arthritis drug no better than standard care for severe COVID-19on January 21, 2021 at 3:50 pm
Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical covid-19 is no better than standard care alone in improving clinical outcomes at 15 days, ...
- Arthritis Drug Tocilizumab Flops as COVID-19 Treatmenton January 21, 2021 at 7:09 am
The arthritis drug tocilizumab doesn't help hospital patients with severe COVID-19, according to a new study that contradicts earlier research suggesting that it might aid recovery. In fact, patients ...
- Latest report on Rheumatoid Arthritis Drugs/Therapeutics Market size with growing CAGR of 4.5% by 2026on January 21, 2021 at 3:20 am
Rheumatoid Arthritis Drugs/Therapeutics Market Report covers the companies' data, including Growth potential analysis, Executive Summary, Data sources, Industry segmentation, Porter’s analysis, ...
- Roche Arthritis Drug Didn’t Help All Covid Patients in Studyon January 21, 2021 at 12:41 am
Roche Holding AG’s arthritis drug Actemra doesn’t help all Covid-19 patients, and in fact might harm some, Brazilian researchers said in the latest seemingly contradictory study results to emerge on ...
- NICE recommends Jyseleca® (filgotinib) on NHS in landmark decision for rheumatoid arthritison January 20, 2021 at 11:48 pm
NICE guidance, for the first time in the UK, supports access to an advanced therapy for people with moderate as well as severe rheumatoid arthritis (RA) - aiming to avoid irreversible damage as early ...
- Conflicting COVID-19 results for Roche arthritis drug show more trials neededon January 20, 2021 at 8:33 pm
Larger trials are needed to assess whether Roche's arthritis drug tocilizumab can cut death rates among the sickest COVID-19 patients, scientists said on Wednesday, after a small study found it was no ...
- Rheumatoid arthritis: thousands set to benefit from drug after NHS approvalon January 20, 2021 at 5:00 pm
Thousands of people with rheumatoid arthritis (RA) are set to benefit from a drug that has been approved for NHS use which could halt the disease before it is too late and irreversible damage is done.
- New trial finds arthritis drug tocilizumab no better than standard care for severe COVID-19on January 20, 2021 at 3:41 pm
Adding the arthritis drug tocilizumab to standard care for patients in hospital with severe or critical COVID-19 is no better than standard care alone in improving clinical outcomes at 15 days, finds ...
- The Latest: Trial of arthritis drug for COVID-19 is haltedon January 20, 2021 at 2:35 pm
An arthritis drug tried in patients with severe COVID-19 showed no benefit in a study that was stopped early because of safety concerns. The study was published Wednesday in the British journal The ...
via Bing News
